Yu, HaipengBolan, ZhuWan, YangQian, ZhangWei, WangWeichun, ZhaiLixia, LuYing, ZhengZheng, DangBin, LiChuyi, LiBin, LiangJiucong, ZhangXiaohui, Yu2020-11-182020-11-182020-05Yu Haipeng, Bolan Zhu, Wan Yang, Qian Zhang, Wei Wang, Weichun Zhai, Lixia Lu, Ying Zheng, Zheng Dang, Bin Li, Chuyi Li, Bin Liang, Jiucong Zhang, Xiaohui Yu. Matrine inhibits proliferation and migration of HepG2 cells by downregulating ERK1/2 signaling pathways. Journal of Cancer Research and Therapeutics. 2020 May; 16(2): 209-2140973-1482http://imsear.searo.who.int/handle/123456789/213802Objective: To research the effect of matrine on the proliferation and migration of HepG2 cells through extracellular signal-regulated kinase 1/2 (ERK1/2) signaling pathway. Methods: HepG2 cell was selected and divided into blank control group, experimental group (matrine 1, 2, and 4 mg/mL), and positive control group (PD98059, ERK1/2 inhibitor). MTT measure was used to detect the effective time and concentration which matrine inhibits HepG2 cells. After 24 h, the effect of effective concentration of matrine on the of morphological changing HepG2 cells was observed. The invasion ability was assayed by transwell method, the expression of ERK1/2 and pERK1/2 were detected through Western blot, and reverse transcription polymerase chain reaction was used to test the expression level of ERK1/2 mRNA. Results: With the increase of matrine concentration, the number of adherent HepG2 cells gradually decreased, the morphologic changes gradually became spherical, some cell morphology was incomplete, and even cell fragments appeared. The proliferation and invasion ability of HepG2 cells decreased. The expression of ERK1/2, pERK1/2, and ERK1/2 mRNA downregulated with the increase of matrine concentration (P < 0.05). Conclusion: Matrine inhibits the proliferation and migration of HepG2 cells by downregulating the ERK1/2 signaling pathway.Extracellular signal regulated kinase 1/2 pathwayhepatocellular carcinomamatrinemigrationproliferationMatrine inhibits proliferation and migration of HepG2 cells by downregulating ERK1/2 signaling pathwaysJournal ArticleIndiaDepartment of Interventional Therapy, Tianjin Medical University Cancer Institute and Hospital; National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin, ChinaDepartment of Gastroenterology, The 940 Hospital of Joint Logistic Support Force of People's Liberation Army, Lanzhou, ChinaDepartment of Gastroenterology, Daxing Teaching Hospital Affiliated to Capital Medical University, Beijing, ChinaDepartment of Hematology, The 940 Hospital of Joint Logistic Support Force of People's Liberation Army, Lanzhou, ChinaDepartment of Gastroenterology, The 940 Hospital of Joint Logistic Support Force of People's Liberation Army, Lanzhou, ChinaDepartment of Gastroenterology, The 940 Hospital of Joint Logistic Support Force of People's Liberation Army, Lanzhou, ChinaDepartment of Gastroenterology, The 940 Hospital of Joint Logistic Support Force of People's Liberation Army, Lanzhou, ChinaDepartment of Hepatobiliary Surgery, The 940 Hospital of Joint Logistic Support Force of People's Liberation Army, Lanzhou, ChinaDepartment of Gastroenterology and Liver Diseases, Ganzhou Fifth People's Hospital, Jiangxi, China